key: cord-0922129-zj4cy1m7
authors: Woodward, Beth; Kermali, Muhammed
title: COVID‐19: The heart of the issue
date: 2020-06-16
journal: J Card Surg
DOI: 10.1111/jocs.14684
sha: 7e0f42731bc173d33c5832f4d59e25febae3a695
doc_id: 922129
cord_uid: zj4cy1m7

nan

To the Editor,

We read with great interest the review by Khan et al 1 who discussed the emerging role of cardiovascular disease and the progression of the novel coronavirus disease 19 (COVID-19). As part of their review, the authors discussed a broad range of cardiovascular effects being observed during and after infection in this disease. We commend their conclusions that appropriate triage and risk stratification is essential in patients with cardiovascular disease (CVD) and COVID-19. We encourage the need for further evidence regarding the mechanisms of CVD and particularly the use of therapeutics. This is of particular importance given the global concern about the use of the renin-angiotensin-aldosterone system (RAAS) inhibitors in the mechanisms of severe acute respiratory distress syndromecoronavirus-2 (SARS-CoV-2). We support the conclusion made that there is currently limited evidence to recommend their use should be discontinued prophylactically and in confirmed cases. 3, 4 It is pivotal further preclinical studies are carried out to understand the cardiovascular mechanisms in COVID-19. We emphasize the need to elucidate mechanisms of RAAS inhibitors in SARS-CoV-2 infection.

Robust and collaborative human studies are needed to apply this understanding in a meaningful way, where major confounding variables, such as advancing age, can be accounted for.

The authors declare that there are no conflict of interests.

Beth Woodward BMedSc (Hons) 1 Muhammed Kermali 2 1

At the heart of COVID-19

Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Inhibitors of the renin-angiotensin-aldosterone system and COVID-19

ACE inhibitors and COVID-19: we don't know yet